A New Framework for Understanding Hair‐Driven Medical Decisions

It is widely recognized that hair contributes significantly to self-image and identity, and that hair loss can trigger a range of negative psychological outcomes. Less appreciated, however, is the extent to which the fear or reality of hair loss can shape patients' medical decisions. I find myself increasingly providing care to patients who made difficult decisions to refuse cancer treatments, halt reproductive plans, decline surgery, or endure treatment-related side effects in order to protect or restore their hair. These patients represent a clinically relevant and ethically complex phenomenon that medicine has yet to fully recognize. To address this gap in clinical awareness and research, I propose the “HairFirst Groups” framework—five distinct categories of patients who prioritize hair preservation above conventional medical recommendations (Table 1). With published data on this phenomenon being limited, I hope to highlight the need for continued study of hair prioritizing behaviors and the impact they have on patient decision-making. Such efforts will help us better recognize and care for patients in these groups. Patient continues a drug (e.g., finasteride or oral minoxidil) despite experiencing significant adverse effects Postmenopausal female continues oral contraceptives well beyond age 50 in order to postpone potential hair-related consequences of stopping Chemotherapy-induced alopecia (CIA) remains one of the most feared and distressing consequences of cancer treatment. Today, up to 50% of women undergoing chemotherapy report hair loss as the most emotionally devastating part of their cancer journey. An estimated 8% of patients decline potentially lifesaving chemotherapy due to fear of losing their hair [1]. But the issue extends beyond conventional chemotherapy. Many targeted therapies, endocrine agents, and immune checkpoint inhibitors are also associated with alopecia. When hair loss occurs, some patients choose to delay or stop treatment, placing hair preservation above the potential for cancer cure. These decisions are not irrational but reflect the profound emotional distress that accompanies hair loss. The field of oncology has long been ahead of other specialties in recognizing hair-related distress and its impact on patient decision-making, but this area remains understudied. Hair loss doesn't just affect appearance—it can also reshape some of life's most personal decisions—including whether and how to have children. Women with androgenetic alopecia (AGA) may experience a postpartum telogen effluvium that triggers irreversible acceleration of AGA. For some, this lasting hair loss can be emotionally traumatic and generate a fear so profound that they reconsider future pregnancies altogether (Group 2A). Others grapple with the distressing possibility of genetically passing on alopecia areata (AA) or AGA to their children. These reproductive anxieties are well recognized in autoimmune diseases like lupus and multiple sclerosis but remain overlooked in the field of hair disorders. Hair loss concerns also arise in the context of assisted reproduction. Patients undergoing in vitro fertilization (IVF) also report significant distress over hair loss related to hormone treatments. A recent study by Kamili et al. [2] revealed a subset of patients who considered halting fertility treatment specifically because of hair loss. As IVF use rises globally, this dilemma will likely become even more of a concern. Collaborative research between gynecologists and dermatologists is needed. In contrast, some women go to great lengths to protect their hair during pregnancy—even when it poses risks to fetal health (Group 2B). For example, Desai et al. [3] described a patient with AA who used topical diphencyprone during pregnancy, despite medical warnings from her physicians not to do so. This highlights yet another case in which hair preservation was prioritized above other medical advice. In the postpartum period, a proportion of patients with preexisting hair loss often face a dilemma: breastfeed their newborn or resume hair loss treatments without breastfeeding (HairFirst Group 2C). In my practice, many postpartum patients with AGA express a strong desire to restart oral minoxidil, and many with advanced AA wish to resume their JAK inhibitors. These patients prioritize hair health over the well-established benefits of breastfeeding. These are not careless decisions—they reflect the desperate need to regain control over hair loss. Fear of hair loss can become a powerful deterrent to surgery. Some patients delay or decline elective and even medically necessary surgery because they fear postoperative telogen effluvium or permanent scalp scarring. For example, Kridel and Liu [4] recently documented patients who declined surgery to avoid hair loss. I have encountered patients who refuse or postpone various surgeries due to fear that general anesthesia would trigger excessive shedding. These decisions may seem minor to clinicians, but to patients they represent a trade-off between treating one condition and risking new psychological trauma from hair loss. The potential for hair loss has the power to affect not only the treatments that patients avoid but also the treatments they endure. Some patients are reluctant to begin common medications such as antidepressants, blood pressure medications, statins, or even routine vaccinations based on the perceived risk of hair loss (Group 4A). These hesitations can lead to preventable illness and missed opportunities for intervention. When a devastated patient with drug-induced telogen effluvium from a beta-blocker tells her cardiologist, “my hair matters more to me than my heart,” it is not surprising that the initial reaction is disbelief. Yet this stark declaration reflects the profound connection between hair, identity and self-worth. At the same time, other patients demonstrate the opposite risk profile—choosing to continue hair-preserving treatments like oral minoxidil or finasteride despite significant side effects (Group 4B). Some postmenopausal women continue oral contraceptives well into their 50s due to fear of the hair loss related consequences of stopping. For these individuals, identity preservation outweighs safety. These patterns warrant greater study. Finally, we must recognize the subset of patients who avoid weight loss strategies out of fear of hair loss. These patients may decline calorie restriction or weight loss medication because of concerns about hair loss. Recent observational data suggest that GLP-1 receptor agonists like semaglutide and tirzepatide may trigger hair loss in a subset of users [5]. For many patients, that possibility alone is enough to forgo the substantial benefits of treatment. These decisions are not superficial—they are deeply personal calculations about identity, visibility, and vulnerability. The HairFirst Groups framework challenges all of us to consider the possibility that the impact of a medical decision on a patient's hair could be a key factor in the choices that the patient ultimately makes. This is not vanity but a human response to loss, shame, and identity disruption. When we fail to acknowledge this, we invite serious consequences—missed screenings, skipped treatments, unreported nonadherence, emotional distress, and mistrust in medical care. The prevalence of HairFirst groups remains uncertain and will need appropriate study. They may represent a small minority or a much larger population than currently appreciated. One thing is for sure—humans differ greatly in how they prioritize hair. Dedicated research is needed to define the frequency and best management strategies for these groups. Hair-related decision-making should be openly discussed in clinics, integrated into counseling tools (Table 2) and systematically studied. By doing so, we can better honor patient values, improve adherence, strengthen trust, and support shared decision-making across medicine. Until then, we risk overlooking a group of patients whose choices fall outside of traditional risk–benefit frameworks. Patients sometimes need time to reflect on their views Some medical decisions are so emotionally charged that patients have not given themselves the opportunity to work through their own views. Open ended questions can be therapeutic Experts may provide helpful numbers, statistics, and odds based on both their knowledge of the literature and personal clinical experience that influence the patient's ultimate decision Experts may also provide strategies for addressing various issues that the patient has not thought about Dr. Jeffrey Donovan has received honoraria from Pfizer and Vichy, has participated on advisory boards at Pfizer for payment, receives royalties from UpToDate, participates on the Board of Directors for the Scarring Alopecia Foundation, and is the active Director of the Evidenced-Based Hair Training Program. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.